The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

Among the various therapeutic categories, anti-infective drugs continue to dominate the Indian market with c17% share (this excludes anti-HIV ... after Abbott and Cipla. Remaining MNCs include ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

In January, the White House ordered an immediate halt to the distribution of HIV medications by U.S.-funded foreign clinics, ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), ...

This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries.

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

In cell lines, the HIV/AIDS drug efavirenz inhibited the replication by almost 99% even at low micromolar concentrations. In the case of mice, the efavirenz treatment “significantly” reduced ...

HIV commodities worth about Sh30 billion are lying at the Mombasa Road warehouses of the Mission for Essential Drugs & Supplies (MEDS), awaiting distribution, the NSDCC has said. The consignment ...

He said people as young as 13 were contracting HIV through intravenous drug use. Health authorities also warn the alarming practice of "bluetoothing" is exacerbating the problem. It involves ...